Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
CORCEPT THERAPEU RG (NQ: CORT)
17.34 USD  -0.08 (-0.46%)
Official Closing Price  /  Updated: 8:00 PM EDT, Apr 24, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 805,257
Open 17.61
Bid (Size) 17.25 (300)
Ask (Size) 18.64 (100)
Prev. Close 17.42
Today's Range 17.15 - 17.99
52wk Range 8.995 - 25.96
Shares Outstanding 114,830,345
Dividend Yield N/A
Performance
YTD
-4.41%
-4.41%
1 Month
+3.28%
+3.28%
3 Month
-31.84%
-31.84%
6 Month
-8.69%
-8.69%
1 Year
+88.48%
+88.48%
Top News
More News
Stocks With Rising Relative Price Strength: Corcept Therapeutics
Corcept Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83. Read More
from Investor's Business Daily
Stock Review for Biotech's Investors -- Concert Pharma, ContraVir Pharma, Corbus Pharma, and Corcept Therapeutics
from PR Newswire
More News
Read More
Stocks With Rising Relative Price Strength: Corcept Therapeutics
from Investor's Business Daily
Corcept Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold
from Investor's Business Daily
Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents
from GlobeNewswire News Releases
Corcept Therapeutics Reaches 80-Plus Relative Strength Rating Benchmark
from Investor's Business Daily
Stocks To Watch: Corcept Therapeutics Sees RS Rating Rise To 83
from Investor's Business Daily
New Research: Key Drivers of Growth for Corcept Therapeutics, HubSpot, Tableau Software, Balchem, Steelcase, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
from GlobeNewswire News Releases
Corcept Therapeutics Trying To Close In On Key Technical Benchmark
from Investor's Business Daily
Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial
from GlobeNewswire News Releases
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call
from GlobeNewswire News Releases
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial